• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics, TypeZero ink development deal for artificial pancreas

May 12, 2017 By Sarah Faulkner

SenseonicsSenseonics (NYSE:SENS) said yesterday that it inked a non-exclusive R&D license agreement with TypeZero Technologies to develop artificial pancreas and decision support systems for its Eversense continuous glucose monitor.

The companies plan to integrate glucose readings from the Eversense system with TypeZero’s inControl artificial pancreas algorithms to regulate insulin delivery through a user’s insulin pump. The integration will also allow TypeZero’s decision support system to recommend basal and bolus doses for insulin pen users.

The deal is the 1st effort to combine a 90-day CGM sensor with smart algorithms for closed loop and decision support applications, the companies reported.

“We’re thrilled to partner with TypeZero with the goal of progressing the diabetes management field in providing solutions to help minimize the burden of diabetes for millions of people,” Senseonics’ president & CEO Tim Goodnow said in prepared remarks. “It is particularly gratifying that the combined Eversense and inControl platform is intended to be used by either insulin pumpers or insulin pen users. The continuous long-term use of an accurate sensor such as Eversense combined with the clinically proven treatment algorithms of inControl has the promise of impacting both pump and pen users in a positive and meaningful way.”

“We see the combination of our inControl technology with Senseonics’ sensor as potentially a huge win for persons with diabetes,” TypeZero CEO Chad Rogers added. “In many ways CGM data is the heartbeat of our artificial pancreas and decision support technologies, and integrating our inControl platform with the reliable and durable Eversense CGM System which could give patients yet another tool for managing their health and simplifying their lives.”

Filed Under: Diabetes, Drug-Device Combinations, Featured, Research & Development, Wall Street Beat Tagged With: Senseonics, typezerotechnologies

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS